ESALF
Eisai Co., Ltd.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
29.90
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
29.90
Day high
29.90
Day low
29.90
Volume
100
Market cap
$8.44B
P/E (TTM)
34.77
52W range
23.88 – 35.83
Trailing performance
Returnvs SPY
1W
+4.14%
+5.3%
1M
+14.21%
+10.9%
3M
+6.79%
+4.4%
6M
-9.39%
-21.3%
YTD
+0.57%
-11.4%
1Y
-7.11%
-27.3%
3Y
-53.18%
-128.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ESALF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
6.15M
Total on file
Fundamentals
Market cap$8.44B
Enterprise value$-5.36B
Revenue (TTM)$857.06B
Gross profit$657.35B
EBITDA$96.13B
Net income$42.33B
EPS (TTM)$0.86
Free cash flow$-27.57B
Total cash$311.74B
Total debt$271.34B
Book value / share$20.23
Shares outstanding282.24M
Float281.16M
Short % of float—
Dividend yield3.39%
Beta (5Y)-0.05
Valuation & profitability ratios
Trailing P/E34.77
Forward P/E23.73
PEG ratio—
Price / sales—
Price / book1.48
EV / revenue-0.01
EV / EBITDA-0.06
Gross margin76.70%
Operating margin10.55%
Profit margin4.94%
Return on equity4.96%
Return on assets2.40%
Debt / equity29.08
Current ratio2.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $825.38B | $789.40B | $741.75B | $744.40B | +4.6% |
| Operating revenue | $825.38B | $789.40B | $741.75B | $744.40B | +4.6% |
| Cost of revenue | $191.22B | $168.81B | $155.33B | $177.84B | +13.3% |
| Gross profit | $634.15B | $620.59B | $586.42B | $566.57B | +2.2% |
| Research & development | $158.66B | $171.63B | $169.02B | $173.00B | -7.6% |
| Selling, general & admin | $435.29B | $407.98B | $374.42B | $358.29B | +6.7% |
| Total operating expense | $590.02B | $566.22B | $533.01B | $526.53B | +4.2% |
| Operating income | $44.14B | $54.38B | $53.41B | $40.04B | -18.8% |
| Net interest income | $6.86B | $6.69B | $8.42B | $4.97B | +2.6% |
| Pre-tax income | $51.00B | $61.06B | $61.82B | $45.01B | -16.5% |
| Tax provision | $10.48B | $13.01B | $18.04B | -$11.82B | -19.4% |
| Net income | $38.56B | $46.43B | $42.41B | $55.43B | -17.0% |
| Net income to common | $38.56B | $46.43B | $42.41B | $55.43B | -17.0% |
| Basic EPS | 136.78 | 163.76 | 147.86 | 193.31 | -16.5% |
| Diluted EPS | 136.78 | 163.76 | 147.86 | 193.31 | -16.5% |
| EBIT | $56.33B | $64.58B | $64.21B | $47.28B | -12.8% |
| EBITDA | $95.88B | $104.49B | $103.61B | $87.26B | -8.2% |
| Basic shares | 281.90M | 283.54M | 286.80M | 286.76M | -0.6% |
| Diluted shares | 281.90M | 283.54M | 286.80M | 286.76M | -0.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $245.42B | $265.56B | $304.68B | $267.35B | -7.6% |
| Cash & short-term investments | $246.31B | $266.05B | $305.12B | $267.89B | -7.4% |
| Accounts receivable | $227.00B | $220.02B | $217.21B | $187.26B | +3.2% |
| Inventory | $257.55B | $215.91B | $174.65B | $140.42B | +19.3% |
| Total current assets | $761.64B | $727.66B | $722.98B | $622.20B | +4.7% |
| Property, plant & equipment | $161.04B | $158.09B | $164.89B | $166.63B | +1.9% |
| Goodwill & intangibles | $347.32B | $308.70B | $321.86B | $298.05B | +12.5% |
| Total assets | $1.45T | $1.39T | $1.39T | $1.26T | +4.5% |
| Total current liabilities | $340.25B | $372.29B | $304.47B | $298.94B | -8.6% |
| Current debt | $51.30B | $87.69B | $24.63B | $41.20B | -41.5% |
| Long-term debt | $134.78B | $99.83B | $134.77B | $84.90B | +35.0% |
| Total debt | $186.08B | $187.52B | $159.41B | $126.11B | -0.8% |
| Total liabilities | $523.99B | $520.58B | $494.82B | $440.78B | +0.7% |
| Retained earnings | $510.92B | $511.92B | $526.49B | $522.77B | -0.2% |
| Shareholder equity | $898.99B | $841.42B | $875.61B | $799.96B | +6.8% |
| Working capital | $421.38B | $355.37B | $418.51B | $323.26B | +18.6% |
| Net tangible assets | $551.67B | $532.71B | $553.75B | $501.91B | +3.6% |
| Shares issued | 291.65M | 291.65M | 296.57M | 296.57M | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $51.00B | $61.06B | $61.82B | $45.01B | -16.5% |
| Depreciation & amortisation | $39.55B | $39.91B | $39.40B | $39.98B | -0.9% |
| Change in working capital | -$13.36B | -$48.26B | -$27.25B | -$61.51B | +72.3% |
| Operating cash flow | $61.32B | $30.12B | $55.99B | -$1.77B | +103.6% |
| Capital expenditure | -$41.17B | -$22.97B | -$24.82B | -$34.56B | -79.2% |
| Investing cash flow | -$41.80B | -$10.10B | -$25.32B | -$22.72B | -313.9% |
| Share buybacks | -$9.00M | -$30.11B | -$21.00M | — | +100.0% |
| Dividends paid | -$45.14B | -$45.55B | -$45.91B | -$45.89B | +0.9% |
| Financing cash flow | -$61.10B | -$57.81B | -$22.72B | -$24.52B | -5.7% |
| Free cash flow | $20.16B | $7.15B | $31.17B | -$36.33B | +182.0% |
| End cash position | $245.42B | $265.56B | $304.68B | $267.35B | -7.6% |
| Line item | 2025-06-30 | YoY |
|---|---|---|
| Basic EPS | 51.35 | |
| Basic shares | 281.87M | |
| Diluted shares | 281.87M |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $245.42B | $301.65B | $265.56B | -18.6% |
| Cash & short-term investments | $246.31B | $302.12B | $266.05B | -18.5% |
| Accounts receivable | $227.00B | $224.06B | $220.02B | +1.3% |
| Inventory | $257.55B | $236.46B | $215.91B | +8.9% |
| Total current assets | $761.64B | $790.70B | $727.66B | -3.7% |
| Property, plant & equipment | $161.04B | $154.43B | $158.09B | +4.3% |
| Goodwill & intangibles | $347.32B | $315.63B | $308.70B | +10.0% |
| Total assets | $1.45T | $1.44T | $1.39T | +0.8% |
| Total current liabilities | $340.25B | $378.25B | $372.29B | -10.0% |
| Current debt | $51.30B | $101.91B | $87.69B | -49.7% |
| Long-term debt | $134.78B | $134.75B | $99.83B | +0.0% |
| Total debt | $186.08B | $236.66B | $187.52B | -21.4% |
| Total liabilities | $523.99B | $558.23B | $520.58B | -6.1% |
| Retained earnings | $510.92B | $517.34B | $511.92B | -1.2% |
| Shareholder equity | $898.99B | $854.43B | $841.42B | +5.2% |
| Working capital | $421.38B | $412.45B | $355.37B | +2.2% |
| Net tangible assets | $551.67B | $538.80B | $532.71B | +2.4% |
| Shares issued | 291.65M | 291.65M | 282.12M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $216.42B | +9.7% |
| Next quarter | — | — | $244.22B | +11.1% |
| Current year | — | — | $905.56B | +134.5% |
| Next year | — | — | $960.86B | +6.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders2.18%
Held by institutions56.58%
Institutions holding279
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
29.19
+2.45% from price
SMA 20
28.51
+4.88% from price
SMA 50
26.58
+12.48% from price
SMA 100
27.58
+8.39% from price
SMA 200
28.71
+4.15% from price
EMA 12
29.11
+2.73% from price
EMA 26
28.22
+5.96% from price
EMA 50
27.60
+8.32% from price
RSI (14)
71.6
Overbought
MACD (12,26,9)
0.89
Hist 0.09
ATR (14)
0.17
0.56% of price
Realised vol 30D
63.0%
Annualised
Bollinger upper
31.09
20, 2σ
Bollinger lower
25.92
20, 2σ
50 / 200 cross
Death
26.58 vs 28.71
Trend bias
Above 200
+4.15%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.06
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
63.0%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-33.4%
Peak to trough
Max drawdown 5Y
-72.9%
Peak to trough
ATR 14
0.17
0.56% of price
Beta (reported)
-0.05
5Y monthly, from filing
Dividends & splits
Forward rate$1.01 / yr
Forward yield3.39%
5-year avg yield2.81%
Payout ratio116.98%
Ex-dividend dateSep 29, 2026
Next pay dateMay 24, 2018
Last split—
Split date—
Headlines
Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease
MT Newswires · 2h ago
Leqembi Iqlik® for initiation treatment launched in the US
PR Newswire · 2h ago
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
GlobeNewswire · 2h ago
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
PR Newswire · 2h ago
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More
GlobeNewswire · 17d ago
Why Biogen Stock Is Resisting a Market Downturn After Earnings
Barrons.com · 26d ago
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
PR Newswire · 26d ago
Eisai and CORE Biomedicine agree on global licence for oncology pipeline
Hospital Management · 26d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.